Almirall SA
MAD:ALM

Watchlist Manager
Almirall SA Logo
Almirall SA
MAD:ALM
Watchlist
Price: 12.9 EUR 0.47% Market Closed
Market Cap: 2.8B EUR

Relative Value

The Relative Value of one ALM stock under the Base Case scenario is 15.88 EUR. Compared to the current market price of 12.9 EUR, Almirall SA is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALM Relative Value
Base Case
15.88 EUR
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
38
vs Industry
59
Median 3Y
1.5
Median 5Y
1.5
Industry
2.6
Forward
2.5
vs History
33
vs Industry
0
Median 3Y
-45.9
Median 5Y
20.9
Industry
21.7
Forward
36.3
vs History
36
vs Industry
29
Median 3Y
13.3
Median 5Y
13.1
Industry
16.7
vs History
0
vs Industry
10
Median 3Y
-16.7
Median 5Y
-5.3
Industry
23.1
vs History
3
vs Industry
49
Median 3Y
1.3
Median 5Y
1.4
Industry
2.2
vs History
42
vs Industry
59
Median 3Y
1.5
Median 5Y
1.6
Industry
2.9
Forward
2.4
vs History
41
vs Industry
69
Median 3Y
2
Median 5Y
2.2
Industry
5.5
vs History
15
vs Industry
30
Median 3Y
10.2
Median 5Y
9.6
Industry
13.2
Forward
11.6
vs History
42
vs Industry
12
Median 3Y
31.5
Median 5Y
23.4
Industry
16.8
Forward
30.9
vs History
41
vs Industry
29
Median 3Y
13.3
Median 5Y
13.2
Industry
15.9
vs History
9
vs Industry
8
Median 3Y
17.6
Median 5Y
24.4
Industry
19.2
vs History
4
vs Industry
53
Median 3Y
1
Median 5Y
1.1
Industry
1.9

Multiples Across Competitors

ALM Competitors Multiples
Almirall SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Almirall SA
MAD:ALM
2.8B EUR 1.7 49.9 10.4 24.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
207B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
ES
Almirall SA
MAD:ALM
Average P/E: 26.8
49.9
150%
0.3
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBITDA: 399.9
10.4
20%
0.5
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBIT: 1 712.4
24.1
56%
0.4
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3